# Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/randomized-phase-iii-trial-of-amrubicin-cisplatin-versus-etoposide-cisplatin-as/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Yan Sun,Ying Cheng,Xuezhi Hao,Jie Wang,Chengping Hu,Baohui Han,Xiaoqing Liu,Li Zhang,Huiping Wan,Zhongjun Xia,Yunpeng Liu,Wei Li,Mei Hou,Helong Zhang,Qingyu Xiu,Yunzhong Zhu,Jifeng Feng,Shukui Qin,Xiaoyan Luo |
| Citations | 45 |
| DOI | 10.1186/s12885-016-2301-6 |
| Fields | Medicine |
| Open Access | true |
| OA Status | gold |
| OA URL | https://bmccancer.biomedcentral.com/counter/pdf/10.1186/s12885-016-2301-6 |
| OpenAlex ID | https://openalex.org/W2333245346 |
| PMID | 27061082 |
| Type | article |
| Year | 2016 |

## Paper authors

- [Xuezhi Hao](https://scholariq.org/researchers/xuezhi-hao/)

## Paper journal

- [BMC Cancer](https://scholariq.org/journals/bmc-cancer/)

## Paper primary topic

- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

## Paper topics

- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Neutropenia and Cancer Infections](https://scholariq.org/topics/neutropenia-and-cancer-infections/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.